Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials | GenomeWeb

By Ben Butkus

German molecular diagnostics firm Curetis said this week that it has netted an additional €4.5 million ($6.4 million) in its Series A financing round, raising its total to €24.5 million in three tranches.

Curetis will use the cash to accelerate the US commercialization of Unyvero, the company's benchtop automated DNA-testing platform, and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic resistance markers, company officials said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.